Dyadic to present disruptive c1 technology at world vaccine congress europe announcing expansion of influenza pipeline with enhanced efficacy potential

Jupiter, fla., oct. 04, 2022 (globe newswire) -- dyadic international, inc. (“dyadic”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that its chief executive officer, mark emalfarb will be presenting at the upcoming world vaccine congress in barcelona, spain.
DYAI Ratings Summary
DYAI Quant Ranking